Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Publication | Open Access

DOI Full Paper Access

309

Citations

References

2020

Year

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, Sara Lonardi, Fotios Loupakis, Filippo Pietrantonio, Roberto Bordonaro, Tiziana Pia Latiano, Emiliano Tamburini, Daniele Santini,

The Lancet Oncology

OncologyMedicineColorectal CancerPathologyUpfront FolfoxiriMetastatic Colorectal CancerCancer TreatmentPharmacologyRadiation OncologyMolecular OncologyPhase 3